CARv3-TEAM-E T Cells in Glioblastoma

Sponsor

Marcela V. Maus, M.D.,Ph.D. (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05660369

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

0.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma.

The name of the treatment intervention used in this research study is:

-CARv3-TEAM-E T Cells (or Autologous T lymphocytes).

Condition or Disease	Intervention/Treatment	Phase
Glioblastoma Malignant Glioma Recurrent Glioblastoma Recurrent Glioma	Drug: CARv3-TEAM-E T cells	Phase 1

Detailed Description

This is a non-randomized, open label, single site Phase 1 study to define the appropriate dose of CARv3-TEAM-E and evaluate its safety for the treatment of recurrent or newly diagnosed glioblastoma.

The U.S. Food and Drug Administration (FDA) has not approved CARv3-TEAM-E T Cells as a treatment for any disease. This is the first time that CARv3-TEAM-E T Cells will be given to humans. CARv3-TEAM-E T Cells are made from a person's own collected immune cells (T-Cells) that are genetically changed and then delivered back into the body to try to kill their cancerous cells.

The research study procedures include screening for eligibility, study treatment, including evaluations and follow up visits, blood collections, echocardiograms, and radiologic imaging of tumors.

It is expected participants will receive treatment over a period of approximately 6 weeks with a period of short-term and then long term follow-up of up to 15 years.

It is expected that about 21 people will take part in this research study.

This research study has received funding through an internal grant program.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

21 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs With GBM

Anticipated Study Start Date :

Jun 1, 2023

Anticipated Primary Completion Date :

Jan 1, 2024

Anticipated Study Completion Date :

Jun 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Safety Run-In Phase Participant enrollment will be staggered by 30 days for up to 3 participants. Participants will receive 1 infusion of CARv3-TEAM-E. Phase will be expanded up to 6 participants if any Dose-Limiting Toxicities DLTs occur. After all participants have been enrolled, there will be an evaluation made by the Data Safety Monitoring Board (DSMB) and the FDA to determine the safety of enrollment into additional arms.	Drug: CARv3-TEAM-E T cells Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir. Other Names: Autologous T lymphocyte
Experimental: Arm 1: Recurrent Glioblastoma (GBM), EGFRvIII Positive Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw. CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36. Participants will be followed for 2 years post-treatment.	Drug: CARv3-TEAM-E T cells Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir. Other Names: Autologous T lymphocyte
Experimental: Arm 2: Newly Diagnosed GBM, EGFRvIII Positive Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw. CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36. Participants will be followed for 2 years post-treatment.	Drug: CARv3-TEAM-E T cells Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir. Other Names: Autologous T lymphocyte
Experimental: Arm 3: Recurrent GBM, EGFRvIII Negative Participants will undergo a leukapheresis procedure, or collection of mononuclear T cells via peripheral blood draw. CARv3-TEAM-E will be administered 1x weekly for 6 doses on Days 0, 7, 14, 21, 28, and 36. Participants will be followed for 2 years post-treatment.	Drug: CARv3-TEAM-E T cells Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir. Other Names: Autologous T lymphocyte

Outcome Measures

Primary Outcome Measures

Incidence of Adverse Events (AEs) [From Day 0 to 2 years post-treatment]
Defined as the incidence of ≥ Grade 3-4 adverse events related to CARv3-TEAM-E.
Number of Dose-Limiting Toxicities (DLTs) [up to 6 months]
Defined as any related toxicity experienced by run-in cohort of CTCAE v5 grade ≥ 4 Adverse Event

Secondary Outcome Measures

Proportion of Participants with One Infusion [up to 6 months]
The study will be deemed feasible if the proportion of participants enrolled that go on to receive at least one infusion of CARv3-TEAM-E cells is 60% or greater. Applies to participants in run-in cohort and Arms 1 and 3.
Overall Response Rate [Day 0 to 2 years post-treatment]
Defined as the best response recorded from the start of treatment until disease progression/recurrence and evaluated using the Response Assessment in Neuro-Oncology Criteria (RANO).
Overall Survival Rate [From Day 0 to 2 years post-treatment]
Defined as the time from registration to death due to any cause.
Progression Free Survival (PFS) [Registration to 2 years post-treatment]
Defined as the time from registration to the earlier of progression or death due to any cause.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

-Safety Run In Arm and ARM 1: Recurrent GBM, EGFRvIII mutant

Participants must have histologically confirmed recurrent GBM or molecular features of GBM with presence of EGFRvIII mutation within 30 days of consent. MGMT methylated, unmethylated, or unknown is allowed.
Participants must be at first progression or recurrence and have at least received prior radiation. Prior temozolomide is not required if the participant is MGMT unmethylated.

Participants must be 4 weeks from prior alkylating therapy or immunotherapy and ≥ 5 half-lives from another investigational agent. No washout is required from radiation since participants will need histological confirmation of recurrence to participate.

ARM 2: Newly Diagnosed GBM, EGFRvIII mutant
Participants must have histologically confirmed newly diagnosed GBM with presence of EGFRvIII mutation and their tumors must be MGMT unmethylated.
Treatment planned with involved field radiation alone without concomitant or sequential temozolomide.
ARM 3: Recurrent GBM, EGFRvIII negative (will only open once safety is confirmed in Arms 1 and 2)
Participants must have histologically confirmed recurrent GBM with absence of EGFRvIII mutation within 30 days of consent but with EGFR amplification.
Participants must be at first recurrence and have at least received prior radiation. Prior temozolomide is not required if the participant is MGMT unmethylated. Participants must be 4 weeks from prior alkylating therapy or immunotherapy and ≥ 5 half-lives from another investigational agent. No washout is required from radiation since participants will need histological confirmation of recurrence to participate.
ALL ARMS:
Participants must have measurable disease, defined as at least one lesion ≥10 mm (≥1 cm) with MRI. Patients cannot have posterior fossa or intramedullary spine-only disease. Leptomeningeal disease is allowed anywhere in the neuroaxis. See Section 11 (Measurement of Effect) for the evaluation of measurable disease.
Resolution of AEs from any prior systemic anticancer therapy or radiotherapy to Grade 1 or baseline (except Grade 2 alopecia and Grade 2 sensory neuropathy)
Medically able and willing to undergo placement of an Ommaya reservoir.
Steroid dose anticipated to be ≤ 4 mg of dexamethasone a day or equivalent at time of first CAR-v3-TEAM-E infusion.
Age ≥18 years
Karnofsky ≥60% (see Appendix A).
Must be able to undergo an MRI with contrast.
Life expectancy of greater than 3 months.
Participants must have adequate organ and marrow function as defined below:
absolute neutrophil count ≥1,000/mcL
platelets ≥80,000/mcL
total bilirubin ≤ institutional upper limit of normal (ULN)
AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN
creatinine ≤ institutional ULN OR
glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2

For patients with Gilbert's syndrome, total bilirubin can be ≤ 3xULN.

Participant has no prior history of malignancy, unless the subject has been free of the disease for ≥5 years with the exception of the following noninvasive malignancies:
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Carcinoma in situ of the cervix
Carcinoma in situ of the breast
Incidental histologic finding of prostate cancer (T1a or T1b) or prostate cancer that is curative
Left ventricular ejection fraction >50% as determined by TTE.
The effects of CARv3-TEAM-E on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of CARv3-TEAM-E administration.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Intraparenchymal posterior fossa disease
Intramedullary spinal disease as the only site of disease.
Prior EGFRvIII targeted therapies.
Treatment with an any prior gene-therapy or gene-modified cellular therapy.
Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above physiologic dosing). Intermittent topical, inhaled, or intranasal corticosteroids are allowed
Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
Participants who are receiving any other investigational agents.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CARv3-TEAM-E (ex. cetuximab).
Participants with uncontrolled intercurrent illness.
Human immunodeficiency virus (HIV)-infected participants are not eligible.
Participants with evidence of chronic hepatitis B virus (HBV) infection or active hepatitis C virus (HCV) infection are not eligible.
Participants with psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CARv3-TEAM-E , breastfeeding should be discontinued if the mother is treated with CARv3-TEAM-E.
For Arm 2, prior to CARv3-TEAM-E Infusion, the following criteria should be confirmed in addition to the relevant criteria above:
Participants must have completed 75% of the planned 6 weeks of involved field radiation without temozolomide
Tumor location and size criteria as in 3.1.7 above.
Prior cancer directed therapy other than radiation is not allowed.